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The influence of AS03A, a tocopherol oil-in-water emulsion-based adjuvant system, on humoral and cell-
mediated responses to A/California/7/2009 H1N1 pandemic vaccine was investigated. In two observer-blind
studies, a total of 261 healthy adults aged 18 to 60 years were randomized to receive either AS03A-adjuvanted
H1N1 vaccine containing 3.75 g hemagglutinin (HA) or nonadjuvanted H1N1 vaccine containing 15 or 3.75
g HA on days 0 and 21. Hemagglutination inhibition (HI) antibody and T-cell responses were analyzed up to
day 42. A first dose of AS03A-adjuvanted vaccine (3.75 g HA) or nonadjuvanted vaccine (15 g HA) induced
HI responses of similar magnitudes that exceeded licensure criteria (e.g., 94 to 100% with titers of >40). A
lower response following 3.75 g HA without adjuvant was observed (73% with titers of >40). Following a
second dose, geometric mean HI titers at day 42 were higher for AS03A-adjuvanted vaccine (636 and 637)
relative to nonadjuvanted vaccine (341 for 15 g HA and 150 for 3.75 g HA). Over the 42-day period, the
increase in frequency of A/H1N1/2009-specific CD4 T cells was significantly higher in the adjuvanted group
than in the nonadjuvanted group. There was no evidence of correlation between baseline CD4 T-cell fre-
quencies and day 21 HI antibody titers, while there was some correlation (R  0.35) between day 21 CD4
T-cell frequencies and day 42 HI titers. AS03A adjuvant enhanced the humoral and CD4
 T-cell-mediated
responses to A/H1N1/2009 vaccine. Baseline A/H1N1/2009-specific CD4 T-cell frequencies did not predict
post-dose 1 antibody responses, but there was some correlation between post-dose 1 CD4 T-cell frequencies
and post-dose 2 antibody responses.
Influenza is a highly contagious infectious disease resulting
in acute respiratory illness in all age groups. Influenza vacci-
nation has been employed for many years as a primary tool to
prevent influenza virus infection and its complications during
the annual seasonal epidemics that occur worldwide. More
recently, influenza vaccines have been deployed against the
pandemic A/H1N1/2009 influenza virus (7, 16, 29, 30) and have
also been developed against the highly pathogenic avian influ-
enza A H5N1 virus, which remains a potential pandemic can-
didate (1, 3, 22, 24, 36).
Advances in adjuvant technology are being applied to sev-
eral vaccines under development or already developed in order
to enhance immunogenicity (12, 18, 37) and, thereby, poten-
tially improve vaccine efficacy. In the case of influenza vac-
cines, adjuvant is included to address three challenges. The
first is the lower response to influenza vaccines observed in
elderly subjects relative to younger adults, which is due to the
decline in immune function with increasing age (14, 26, 27, 39).
This is particularly an issue for seasonal influenza, which dis-
proportionally affects the elderly (34, 35). The second is the
rate-limiting nature of influenza antigen production, which is
primarily an issue for pandemic influenza when large supplies
of vaccine are required in a short time frame. If immunoge-
nicity can be significantly improved by the use of an adjuvant
system, then less antigen is required and more vaccine doses
can be produced. The third challenge is antigenic drift leading
to suboptimal vaccine protection when the vaccine antigen
(strain) differs too much from the influenza virus strain that
causes the seasonal or pandemic outbreak (4).
The tocopherol oil-in-water emulsion-based adjuvant system
AS03 has been successfully employed to enhance the humoral
immunogenicity of H5N1 vaccines (22). In addition to antigen
sparing, AS03 also promoted cross-immunity against drifted
H5N1 strains (21, 22) and induced protection against heterol-
ogous lethal H5N1 challenge in ferrets (2).
In this report, we investigate in more depth the influence of
AS03 on the immunogenicity of influenza vaccines by evaluat-
ing cell-mediated as well as humoral responses to A/California/
7/2009 H1N1 pandemic vaccines.
MATERIALS AND METHODS
Study design and participants. This report presents data from two separate,
randomized (1:1), observer-blind phase III studies (designated A and B), each
with two parallel groups vaccinated with AS03A-adjuvanted or nonadjuvanted
A/H1N1/2009 vaccine, both conducted in one center in Belgium between Sep-
tember and December 2009. The primary objective of study A was to demon-
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strate that vaccination with two doses of AS03A-adjuvanted A/H1N1/2009 vac-
cine results in a hemagglutination inhibition (HI) immune response that meets or
exceeds European Medicines Agency (EMA) Committee for Medicinal Products
for Human Use (CHMP) criteria (9). The primary objective of study B was to
assess the HI immune response to A/H1N1/2009 vaccine with and without AS03A
in terms of CHMP criteria. In both studies, assessment of safety was a secondary
objective. Exploratory objectives were assessment of cell-mediated immune
(CMI) responses and assessment of HI immune responses stratified by previous
seasonal vaccination.
In both studies, eligible participants were clinically healthy adults between 18
and 60 years of age at the time of vaccination who provided written informed
consent. Subjects with a clinical history suggestive of an influenza infection within
6 months preceding the study start were excluded. Randomization was per-
formed by the sponsor. At the time of vaccination, the responsible on-site
personnel accessed the internet randomization system that used a minimization
procedure accounting for age (between 18 and 40 years inclusive, above 41 to 50
years inclusive, and above 51 to 60 years inclusive at a ratio or 2:1:1).
The protocol and other relevant study documentation were approved by the
appropriate Ethics Committee, and the study was conducted in accordance with
good clinical practice and all applicable regulatory requirements, including the
Declaration of Helsinki.
Study vaccines. The monovalent influenza virus A/H1N1/2009 inactivated,
split-virion vaccine was manufactured by GlaxoSmithKline (GSK) Biologicals
from a vaccine seed virus prepared from the NYMC X-179A strain as recom-
mended by the World Health Organization (WHO) (40). The reassortant virus
NYMC X-179A was prepared by New York Medical College, New York, by a
classical reassortant methodology from the A/California/7/2009 H1N1 virus and
the NYMC X-157A virus (H3N2, hy A/NY/55/2004  A/PR/8/34 [6:2]). The
hemagglutinin (HA), NA, and PB1 genes were donated by A/California/7/2009
H1N1, and the other internal genes (coding for PB2, PA, NP, M, and NS) were
donated by NYMC X-157A.
The seed virus was propagated on embryonated hen eggs, and the vaccine was
produced by using the licensed manufacturing process for Pandemrix (a trade-
mark of the GlaxoSmithKline group of companies). AS03A, a tocopherol oil-in-
water emulsion-based adjuvant system, was manufactured by GSK Biologicals.
Each vaccine was administered at a 0.5-ml injection volume. The AS03A-adju-
vanted vaccine contained 3.75 g hemagglutinin (HA) and 11.86 mg tocopherol,
while the nonadjuvanted vaccine was formulated to contain either 15 g HA
(study A) or 3.75 g HA (study B).
Procedures. As the appearances of the AS03A-adjuvanted and nonadjuvanted
vaccines were different, both studies were observer blind, with vaccinations
performed by specific study personnel not involved in the assessment of safety or
immunogenicity. Vaccine was administered on days 0 and 21. Blood samples
(one for the assessment of antibody responses and one for the assessment of
CMI responses) were collected prior to vaccination (day 0) and following dose 1
(day 21) and dose 2 (day 42). Peripheral blood mononuclear cells (PBMCs) for
the assessment of CMI responses were isolated by Ficoll-Hypaque (Lymphoprep;
Life Technologies, Carlsbad, CA) density centrifugation following standard pro-
cedures. The cells were washed twice in Hanks buffered salt solution and cryo-
preserved in liquid nitrogen until use.
Safety and reactogenicity were evaluated as described previously (30).
Assessment of the humoral immune response. Serum samples were tested in
a validated HI microtiter assay using chicken erythrocytes, as previously de-
scribed (19), with the A/California/7/2009 vaccine strain used as an antigen.
Assessment of T-cell response. An adaptation of the method described by
Maecker et al. (25) was used in which T cells are restimulated ex vivo by
incubation with antigen in the presence of costimulatory antibodies to CD28 and
CD49d (38) and brefeldin A to inhibit cytokine secretion and allow intracellular
accumulation. The cells were then stained with fluorochrome-conjugated anti-
bodies. CD40L (also known as CD154), a well-documented (5, 11) and poten-
tially more specific activation marker (11, 20), was used instead of CD69 (21).
Ex vivo stimuli. We used two ex vivo stimuli: (i) A/California/7/2009 H1N1 split
antigen containing essentially the two major viral surface glycoproteins H1 and
N1 and (ii) an A/California/7/2009 H1 hemagglutinin peptide pool (consisting of
20-mer peptides covering the whole H1 hemagglutinin protein sequence with
15-amino-acid overlaps to ensure all T-cell epitopes are represented) to specif-
ically monitor the T-cell response to H1 antigen. The peptides were synthesized
by Eurogentech, Belgium, and shown to have 85% purity by high-performance
liquid chromatography (HPLC). Lyophilized peptides were reconstituted in
phosphate-buffered saline (PBS)-dimethyl sulfoxide (DMSO) (0.1% final con-
centration).
Antibodies. Antibodies used for cell costimulation were unconjugated and
azide-free anti-CD28 and anti-CD49d. Conjugated antibodies used for staining
were anti-CD4–peridinin chlorophyll a protein (PerCP), anti-CD8–allophycocya-
nin–H7 (APC-H7), anti-gamma interferon (IFN-)–fluorescein isothiocyanate
(FITC), anti-interleukin-2 (IL-2)–allophycocyanin (APC), anti-tumor necrosis
factor alpha (TNF-)–phycoerythrin (PE)–cyanin 7 (PE-Cy7), and anti-CD40L–
phycoerythrin (PE) (all BD Pharmingen, San Diego, CA).
Cell stimulation and staining. Purified PBMCs were thawed, washed twice in
culture medium (RPMI 1640; Cambrex, East Rutherford, NJ) supplemented
with 10% heat-inactivated fetal calf serum (FCS) (PAA Laboratories GmbH,
Austria), 10,000 IU/ml penicillin, 100 g streptomycin sulfate, 200 mM L-glu-
tamine, 100 minimal essential medium (MEM) with nonessential amino acids,
100 mM sodium pyruvate, and 50 mM 2-mercaptoethanol (all from Life Tech-
nologies, Belgium); examined for viability (propidium iodide exclusion using flow
cytometry) and counted (Sysmex); washed again; and resuspended to 2  107
cells/ml in culture medium. PBMCs (106 cells per well) were incubated in 96-well
microtiter plates with costimulatory anti-human CD28 and CD49d antibodies
(1/250 dilution each) and stimulated for 20 h at 37°C with either H1N1 split
antigen from the A/California/7/2009 strain (final concentration, 1 g/ml HA) or
the H1 peptide pool (final concentration, 1.25 g/ml of each peptide). Brefeldin
A (final concentration, 1 g/ml; BD Pharmingen) was added for the last 18 h of
culture. An unstimulated control (no antigen) and positive control (Staphylococ-
cus enterotoxin B, 1 g/ml; Sigma-Aldrich, St. Louis, MO) were included in each
assay. Following incubation, the cells were washed (PBS containing 1% FCS) and
stained with anti-CD4-PerCP and anti-CD8-APC-H7. The cells were then
washed again, fixed, and permeabilized with the Cytofix/Cytoperm kit (BD
Pharmingen) according to the manufacturer’s instructions and stained with
anti-IFN-–FITC, anti-IL-2–APC, anti-TNF-–PE-Cy7, and anti-CD40L–
PE. Following washing (Perm/Wash buffer; BD Pharmingen), the cells were
analyzed by flow cytometry. Antigen-specific CD4 or CD8 T cells were iden-
tified as CD4 or CD8 T cells expressing two or more immune markers after
stimulation.
Flow cytometry and data analysis. Cells were analyzed on a FACSCanto flow
cytometer (Becton Dickinson, San Jose, CA) using 6-color panels. Data were
analyzed with FACSDiva software. Results were expressed as frequencies of
CD4 or CD8 T cells responding to the antigen and expressing two or more
immune markers (among CD40L, IFN-, IL-2, and TNF-) per million total
CD4 or CD8 T cells. Background (unstimulated control) was subtracted from
all values. The remaining positive events were regarded as significant. Samples
were only included for analysis if viability was 80% or more.
Statistical analysis. As planned in the protocol, a final descriptive analysis has
been performed for both studies on the humoral immune response and reacto-
genicity/safety data generated up to day 42. For study A, an additional statistical
analysis has been performed on the CMI responses. Humoral and CMI re-
sponses are presented for the per-protocol immunogenicity cohort and safety
data for the intent-to-treat (total vaccinated) cohort.
The humoral immune response was analyzed by the standard HI test endpoints
with 95% confidence intervals (CIs) used by the EMA CHMP for evaluation of
influenza vaccines (9). The sample size was calculated on the basis of fulfillment
of CHMP criteria for the HI endpoints (9) following two doses of AS03A-
adjuvanted vaccine. A sample size of 64 subjects per group was estimated to give
a power of at least 97%, assuming 88% for seroconversion and seroprotection
rates and an increase of 5.6 to 163 for the geometric mean titer (GMT).
The cellular immune responses were expressed in terms of H1N1 split antigen-
or H1 HA (peptide pool)-specific CD4 T-cell frequency (geometric mean) per
million total CD4 T cells and CD8 T-cell frequency (geometric mean) per
million total CD8 T cells.
Two post hoc analyses were performed on both humoral and CMI response
data. The first analysis was done to assess the benefit of the adjuvant on the CMI
response. An analysis of variance model for repeated measures, including age as
covariates, and gender, time, treatment, and time by treatment as fixed effects
was fitted on the log-transformed frequencies of H1N1- or H1-specific CD4 T
cells identified as expressing two or more immune markers upon in vitro stimu-
lation. The correlation structure of the residuals was selected unstructured, and
the interactions including age and gender were assessed but not kept since not
significant. Based on this model, geometric means (GMs) with their 95% CIs
were reported by time and treatment. The between-treatment ratios of the
postvaccination over prevaccination GM ratios were also computed with their
95% CIs. All computations were performed with SAS 9.1.3.
The objective of the second post hoc analysis was to assess the relationship
between HI postvaccination response and preexisting cellular immunity. The
correlations (i) between individual HI antibody levels on day 21 and H1N1- or
H1-specific CD4 T-cell frequencies observed at baseline and (ii) between HI
antibody levels on day 42 and H1N1- or H1-specific CD4 T-cell frequencies at
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day 21 were estimated by computing Spearman partial correlation coefficients
adjusted by age, sex, history of vaccination, and prevaccination status.
The safety endpoints (percentage of subjects and 95% CIs) were solicited
adverse events and spontaneously reported adverse events. All serious adverse
events occurring up to day 42 were described.
Both trials have been registered with ClinicalTrials.gov under no.
NCT00968539 and NCT00989287.
RESULTS
Study populations. In study A, 130 subjects were enrolled
and vaccinated with either 3.75 g HA of AS03A-adjuvanted
A/H1N1/2009 vaccine (n  64) or 15 g HA of nonadjuvanted
A/H1N1/2009 vaccine (n  66), and 129 subjects completed
the study. In study B, 131 subjects were enrolled and vacci-
nated with either 3.75 g HA of AS03A-adjuvanted A/H1N1/
2009 vaccine (n  65) or 3.75 g HA of nonadjuvanted
A/H1N1/2009 vaccine (n  66), and all completed the study.
Figures 1A and B show the exclusions from immunogenicity
assessment. Demographic profiles for each study are shown in
Table 1. The percentages of subjects who received seasonal
influenza vaccination at least once during the preceding 2 years
were 57.8% in the AS03A-adjuvanted group and 40.9% in the
nonadjuvanted group in study A and 32.3% in the AS03A-
adjuvanted group and 30.3% in the nonadjuvanted group in
study B.
Humoral immune response. HI data are presented in Table
2. Although GMT values were low prior to vaccination (day 0),
antibodies against the vaccine strain were detected (HI titers of
1:10; data not shown) in 38.3% and 42.4% of subjects in the
two study A groups and 45.3% and 31.7% of subjects in the two
study B groups. Overall, 15.1% of subjects in study A and
10.2% of subjects in study B had putatively protective HI titers
of 1:40 prior to vaccination. When stratified by age, the
percentages of subjects with HI titers of 1:40 on day 0 in
studies A and B, respectively, were 16.4% and 19.0% for 18 to
40 years, 18.8% and 3.1% for 41 to 50 years, and 9.1% and 0%
for 51 to 60 years.
Stratification by previous seasonal influenza vaccination (Ta-
ble 3) revealed baseline seroprotection rates and GMTs that
were interpreted as comparable for subjects with and without
a history of seasonal vaccination.
A substantial increase in GMT following the first dose of
either 3.75 g HA of AS03A-adjuvanted vaccine or 15 g HA
of nonadjuvanted A/H1N1/2009 vaccine in study A was ob-
served with amplitudes considered similar in both groups
(335.2 and 310.2). The immune responses in both groups fol-
lowing the first dose met CHMP criteria for influenza vaccines
FIG. 1. (A) Participant flowchart for study A; (B) participant flow-
chart for study B.
TABLE 1. Summary of demographic characteristics per protocol cohorts for immunogenicity
Parameter
Result for:
Study A Study B
AS03A-adjuvanted H1N1
vaccine (3.75 g HA)
Nonadjuvanted H1N1
vaccine (15 g HA)
AS03A-adjuvanted H1N1
vaccine (3.75 g HA)
Nonadjuvanted H1N1
vaccine (3.75 g HA)
Age at vaccination (yr)
Mean (SD) 40.1 (13.40) 38.2 (14.10) 37.2 (14.27) 38.7 (13.70)
Median (range) 44.5 (19–60) 40.5 (18–60) 41.0 (18–60) 41.0 (20–60)
Gender (%)
Female 65.0 59.1 65.6 54.0
Male 35.0 40.9 34.4 46.0
Geographic ancestry (%)
Asian-East Asian 0.0 1.5 0.0 1.6
White-Caucasian/European 100 98.5 100 98.4
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with seroconversion and seroprotection rates (HI titers of 1:
40) of 98.3% and 100% in the AS03A-adjuvanted group and
84.8% and 93.9% in the nonadjuvanted group.
In study B, a first dose of 3.75 g HA of AS03A-adjuvanted
vaccine induced an observed GMT 4-fold higher than the one
estimated after a first dose of 3.75 g HA of nonadjuvanted
A/H1N1/2009 vaccine (424 and 96.4, respectively). The sero-
conversion and seroprotection rates were 93.8% and 93.8% in
the AS03A-adjuvanted group and 69.8% and 73.0% in the
nonadjuvanted group. The immune responses in both groups
met CHMP criteria.
A second dose of 3.75 g HA of AS03A-adjuvanted vaccine




Study A Study B
AS03A-adjuvanted H1N1
vaccine (3.75 g HA)
(n  59 or 60)c
Nonadjuvanted H1N1
vaccine (15 g HA)
(n  66)
AS03A-adjuvanted H1N1
vaccine (3.75 g HA)
(n  64)
Nonadjuvanted H1N1
vaccine (3.75 g HA)
(n  63)
Prevaccination, day 0
GMT (95% CI) 8.8 (7.0–11.1) 10.8 (8.1–14.4) 9.6 (7.6–12.0) 8.4 (6.7–10.6)
Seroprotection rate (titer, 1:40);
% (95% CI)
11.7 (4.8–22.6) 18.2 (9.8–29.6) 10.9 (4.5–21.2) 9.5 (3.6–19.6)
Post-dose 1, day 21
GMT (95% CI) 335.2 (250.1–449.2) 310.2 (218.8–439.7) 424.0 (312.4–575.5) 96.4 (64.0–145.3)
Geometric mean fold rise (95% CI) 38.1 (28.6–50.7) 28.7 (20.0–41.2) 44.4 (33.6–58.7) 11.4 (8.1–16.3)
Seroprotection rate (titer, 1:40);
% (95% CI)
100 (94.0–100) 93.9 (85.2–98.3) 93.8 (84.8–98.3) 73.0 (60.3–83.4)
Seroconversion rate; % (95% CI) 98.3 (91.1–100) 84.8 (73.9–92.5) 93.8 (84.8–98.3) 69.8 (57.0–80.8)
Post-dose 2, day 42
GMT (95% CI) 636.3 (520.9–777.3) 341.0 (259.9–447.3) 686.7 (567.0–831.7) 149.7 (108.0–207.7)
Geometric mean fold rise (95% CI) 72.9 (55.4–95.9) 31.5 (23.1–43.2) 71.9 (57.0–90.7) 17.8 (13.3–23.8)
Seroprotection rate (titer, 1:40);
% (95% CI)
100 (93.9–100) 100 (94.6–100) 100 (94.4–100) 88.9 (78.4–95.4)
Seroconversion rate; % (95% CI) 98.3 (90.9–100) 92.4 (83.2–97.5) 100 (94.4–100) 85.7 (74.6–93.3)
a GMT calculations were performed by taking the antilog of the mean of the log titer transformations. Geometric mean fold rise (seroconversion factor) is defined
as geometric mean of the within-subject ratios of the postvaccination reciprocal hemagglutination inhibition titer to the day 0 reciprocal agglutination-inhibition titer.
The seroconversion rate for the hemagglutination inhibition antibody response is defined as the percentage of vaccines who have a prevaccination titer of 1:10 and
a postvaccination titer of 1:40 or a significant increase in antibody titer defined as the percentage of vaccines who have a prevaccination titer of 1:10 and at least
a 4-fold increase in postvaccination titer.
b The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) criteria for hemagglutination inhibition antibody response in 18 to
60 year olds are a seroprotection rate of 70%, seroconversion rate of 40%, and geometric mean fold rise of 2.5.
c n  60 for prevaccination, day 0, and post-dose 1, day 21, and n  59 for post-dose 2, day 42.
TABLE 3. Immune response stratified by previous seasonal influenza vaccination as determined by hemagglutination inhibition antibodies
against A/California/7/2009 H1N1
Vaccine group Sampling timepoint
Previous seasonal influenza vaccination No seasonal influenza vaccination
n Seroprotection rate (titer,
1:40); % (95% CI) GMT (95% CI) n
Seroprotection rate (titer,
1:40); % (95% CI) GMT (95% CI)
Study A
AS03A-adjuvanted H1N1 Day 0 35 14.3 (4.8–30.3) 9.5 (6.8–13.3) 25 8.0 (1.0–26.0) 7.9 (5.7–10.9)
vaccine (3.75 g HA) Day 21 35 100 (90.0–100) 270.5 (180.9–404.5) 25 100 (86.3–100) 452.6 (296.4–691.0)
Day 42 34 100 (89.7–100) 516.7 (389.6–685.4) 25 100 (86.3–100) 844.6 (654.8–1,089.4)
Nonadjuvanted H1N1 Day 0 27 22.2 (8.6–42.3) 11.6 (7.8–17.5) 39 15.4 (5.9–30.5) 10.3 (6.9–15.4)
vaccine (15 g HA) Day 21 27 92.6 (75.7–99.1) 209.6 (122.6–358.5) 39 94.9 (82.7–99.4) 406.8 (257.1–643.8)
Day 42 27 100 (87.2–100) 226.3 (145.5–352.0) 39 100 (91.0–100) 452.8 (325.9–629.1)
Study B
AS03A-adjuvanted H1N1 Day 0 21 9.5 (1.2–30.4) 10.0 (6.4–15.5) 43 11.6 (3.9–25.1) 9.4 (7.1–12.4)
vaccine (3.75 g HA) Day 21 21 85.7 (63.7–97.0) 289.7 (157.8–531.9) 43 97.7 (87.7–99.9) 510.7 (360.3–724.1)
Day 42 21 100 (83.9–100) 499.7 (347.3–718.9) 43 100 (91.8–100) 802.1 (644.8–997.6)
Nonadjuvanted H1N1 Day 0 17 5.9 (0.1–28.7) 9.4 (6.4–13.7) 46 10.9 (3.6–23.6) 8.1 (6.0–10.8)
vaccine (3.75 g HA) Day 21 17 64.7 (38.3–85.8) 62.6 (29.6–132.2) 46 76.1 (61.2–87.4) 113.2 (68.9–185.9)
Day 42 17 76.5 (50.1–93.2) 83.2 (46.5–148.8) 46 93.5 (82.1–98.6) 186.0 (126.4–273.7)
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induced an observed increase of at least 1.6-fold in HI re-
sponse from day 21 to day 42 (335 to 636 and 424 to 687 in
studies A and B, respectively). Lower GMTs were observed at
day 42 for both nonadjuvanted vaccine formulations (341 for
15 g HA and 150 for 3.75 g HA), although a second dose of
the 3.75-g-HA formulation (but not the 15-g-HA formula-
tion) did induce an increase of 1.5-fold from day 21 to day 42.
Stratification by previous seasonal influenza vaccination (Ta-
ble 3) indicated a trend toward lower GMTs at days 21 and 42
in subjects who had previously received seasonal vaccine. This
trend was evident in both studies and in both AS03A-adju-
vanted and nonadjuvanted vaccine groups.
Cell-mediated immune response (analyzed in study A only).
Geometric means of the frequencies of CD4 T cells and
CD8 T cells specific for A/California/7/2009 H1N1 split an-
tigen or the A/California/7/2009 H1 peptide pool on day 0
(prevaccination), day 21, and day 42 are presented in Table 4.
Plots of the adjusted geometric means of the frequencies of
CD4 T cells are presented in Fig. 2. This analysis demon-
strates that the CD4 T-cell response increased in both vac-
cine groups over the whole 42-day period and that the increase
was significantly higher in the adjuvanted group than that in
the nonadjuvanted group (GM ratio of 2.82 and P  0.0080
with H1N1 split antigen and GM ratio of 1.72 and P  0.0084
TABLE 4. Geometric means of the frequencies of immunological marker-positive CD4 T cells or immune marker-positive CD8 T cells
specific for A/California/7/2009 H1N1 split antigen or H1 peptide poola
Stimulating antigen Vaccine group
Geometric mean/million CD4 or CD8 T cells (CV)
CD4 CD8
Day 0 Day 21 Day 42 Day 0 Day 21 Day 42
H1N1 split antigen Nonadjuvanted H1N1
vaccine (15 g HA)
249.76 (370.82) 627.20 (209.64) 509.49 (310.28) 2.80 (472.00) 2.56 (338.13) 2.71 (517.90)
AS03A-adjuvanted H1N1
vaccine (3.75 g HA)
356.75 (141.84) 1,552.96 (323.60) 2,044.63 (200.45) 3.57 (519.80) 4.61 (794.93) 1.97 (311.29)
H1 peptide pool Nonadjuvanted H1N1
vaccine (15 g HA)
215.73 (115.14) 319.26 (134.23) 471.80 (40.92) 3.03 (457.01) 1.98 (277.97) 5.97 (954.90)
AS03A-adjuvanted H1N1
vaccine (3.75 g HA)
197.90 (126.65) 516.65 (72.97) 741.75 (47.89) 2.61 (470.14) 4.92 (723.98) 5.26 (873.57)
a Marker positive is defined as positive for at least two immunological markers among CD40L, IFN-, IL-2, and TNF-.
FIG. 2. Adjusted geometric means of the frequencies of CD4 T cells specific for A/California/7/2009 H1N1 split antigen or A/California/7/
2009 H1 peptide pool (presented with hemagglutination inhibition antibody geometric mean titers at the same time points).
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with the H1 peptide pool). A significantly higher CD4 T-cell
response was already observed over the period from day 0 to
day 21 in the AS03A-adjuvanted group compared with the
nonadjuvanted group following stimulation with the H1 pep-
tide pool (GM ratio, 1.76; P  0.0104), and although not
significant (P  0.1079), the same trend was observed follow-
ing stimulation with H1N1 split antigen (GM ratio, 1.73). An-
other observation is that the postvaccination GM values
recorded following stimulation with split antigen in the AS03A-
adjuvanted group were higher than those recorded following
stimulation with the H1 peptide pool as well as those recorded
following either stimulus in the nonadjuvanted group.
There was no evidence of a correlation between HI antibody
levels on day 21 after the first vaccination and the frequency of
CD4 T cells specific for A/California/7/2009 H1N1 split an-
tigen observed at baseline (R  0.01) (Fig. 3). There was,
however, some correlation between HI antibody levels on day
42 (after the second vaccination) and the frequency of CD4 T
cells specific for A/California/7/2009 H1N1 split antigen ob-
served at day 21 (R  0.35) (Fig. 4). Similar results were
obtained between HI antibody levels on days 21 and 42 and the
peptide-pool-specific CD4 T cells (R  0.11 and 0.35, respec-
tively).
Vaccination did not have any detectable impact on the fre-
quencies of antigen-specific CD8 T cells (Table 4) as mea-
sured on day 21 or 42.
Reactogenicity and safety. In each study, the observed fre-
quencies of injection site symptoms were higher in the AS03A-
adjuvanted groups than those in the nonadjuvanted groups.
Following both vaccine doses, pain at the injection site was the
only local solicited symptom reported for the nonadjuvanted
groups (35.4% and 30.3% following the first and second doses
in the 15-g-HA nonadjuvanted group in study A and 24.2%
and 17.2% in the 3.75-g-HA nonadjuvanted group in study
B). In the AS03A-adjuvanted groups, injection site pain was
reported in over 89% of subjects following both vaccine doses
but was mainly mild to moderate, with only one to two subjects
with grade 3 pain after each dose. Reports of injection site
redness and swelling were much less frequent, and no cases
were over 100 mm. The median duration of injection site pain
after each dose was 3 days in the AS03A-adjuvanted groups in
both studies (1 to 2 days for grade 3 pain) and 1 to 2 days in the
nonadjuvanted group in both studies (data not shown).
Following the first dose, the most frequently reported sys-
temic solicited adverse event was fatigue (34.9% in the AS03A-
adjuvanted group and 27.7% in the 15-g-HA nonadjuvanted
group in study A and 47.7% in the AS03A-adjuvanted group
and 33.3% in the 3.75-g-HA nonadjuvanted group in study
B). Systemic symptoms tended to occur more frequently in the
AS03A-adjuvanted groups, in particular headache (27.0% ver-
sus 16.9% in study A and 38.5% versus 24.2% in study B) and
muscle aches (31.7% versus 9.2% in study A and 26.2% versus
9.1% in study B).
Following the second dose, fatigue remained the most com-
mon solicited adverse event (45.2% in the AS03A-adjuvanted
group and 19.7% in the 15-g-HA nonadjuvanted group in
study A and 43.8% in the AS03A-adjuvanted group and 23.4%
in the 3.75-g-HA nonadjuvanted group in study B). In both
studies, systemic symptoms were more common in the AS03A-
adjuvanted groups, and in study A, incidences also tended to
be higher in this group than following the first dose. In all
groups and after each vaccine dose, the majority of symptoms
were mild to moderate in intensity, with a median duration of
1 to 3 days, and most were considered by the investigators to be
related to vaccination (data not shown). The incidence of fever
38°C was low (zero to three reports following each dose), and
the rates were similar in both adjuvanted and nonadjuvanted
groups.
In both adjuvanted and nonadjuvanted groups, the percent-
ages of doses followed by at least one spontaneously reported
FIG. 3. Scatter plot of hemagglutination inhibition antibodies at
day 21 versus frequency of CD4 T cells specific for A/California/7/
2009 H1N1 split antigen at day 0 (prevaccination) (per protocol cohort
for immunogenicity). R, Spearman’s partial correlation coefficient ad-
justed by age, sex, history of vaccination, and prevaccination status
(seropositive or seronegative). *, positive for at least two immunolog-
ical markers among CD40L, IFN-, IL-2, and TNF-.
FIG. 4. Scatter plot of hemagglutination inhibition antibodies at
day 42 versus frequency of CD4 T cells specific for A/California/7/
2009 H1N1 split antigen at day 21 (per protocol cohort for immuno-
genicity). R, Spearman’s partial correlation coefficient adjusted by age,
sex, history of vaccination, and prevaccination status (seropositive or
seronegative). *, positive for at least two immunological markers
among CD40L, IFN-, IL-2, and TNF-.
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adverse event within the 42-day period were, respectively,
53.1% and 48.5% in study A and 38.0% and 30.8% in study B.
The percentages of doses followed by at least one spontane-
ously reported grade 3 adverse event were still, respectively,
5.5% and 6.1% in study A and 3.9% and 3.1% in study B. The
percentages of doses followed by spontaneously reported
adverse events considered by the investigators as related to
vaccination were 11.0% in the AS03A-adjuvanted group and
5.3% in the nonadjuvanted group in study A and 13.2% in the
AS03A-adjuvanted group and 8.5% in the nonadjuvanted
group in study B. Two grade 3 spontaneously reported events
considered by the investigators as related to vaccination (in-
fluenza-like illness and malaise) were reported in the AS03A-
adjuvanted group in study A. One subject reported a serious
adverse event (migraine) 14 days after the first vaccination
dose in the nonadjuvanted group in study A; this event, which
resolved, was considered by the investigator as not related to
vaccination.
DISCUSSION
Previously, the AS03 adjuvant system has been administered
with H5N1 vaccines to a large number of adults (6, 22, 32)
without raising any clinically observable safety concerns when
monitored for up to 6 months following two-dose primary
vaccination and also following a third (booster) dose adminis-
tered at 6 months (33) or 14 months (23) after primary vacci-
nation. Data from a smaller number of adults from the two
studies presented here and from a previous study (30) also
indicate no clinically observable safety concerns when AS03 is
administered with A/H1N1/2009 vaccine. This report focuses
on the immune responses and in particular addresses (i) the
impact of the AS03 adjuvant system on humoral and T-cell
responses to A/H1N1/2009, (ii) whether preexisting T-cell
immunity influences postvaccination humoral responses,
and (iii) whether previous seasonal influenza vaccination
influences postvaccination humoral responses. Before ad-
dressing these three points, we first discuss the immune
response to A/H1N1/2009 in the context of experience with
H5N1 and preexisting humoral immunity.
In contrast to the experience with H5N1 where two doses of
nonadjuvanted vaccine with HA levels above 30 g are re-
quired to fulfill licensure criteria in at least more than half of
the vaccinees (3, 22, 36), the results presented here demon-
strate that a single dose of A/H1N1/2009 vaccine containing
either 15 g HA without adjuvant or 3.75 g HA with adjuvant
is highly immunogenic in adults and sufficient to fulfill regula-
tory acceptance criteria for pandemic influenza vaccines. This
suggests the existence of some level of immunological priming
of the population for the A/H1N1/2009 strain, despite the fact
that it is antigenically and genetically distinct from recently
circulating influenza virus A H1N1 strains (13, 15). This is
supported by the observation that, prior to vaccination, 32% to
45% of our Belgian study participants and 48% to 78% of
adults in another study in the United States (29) had baseline
detectable antibodies against the A/H1N1/2009 strain, while
only 0.7% to 3% of subjects in H5N1 vaccine studies had
baseline detectable antibodies against H5N1 strains (3, 22, 33,
36). As subjects with a medical history suggestive of influ-
enza in the 6 months prior to the study were excluded,
preexisting antibodies are unlikely to be due to prior infec-
tion with A/H1N1/2009, although there may have been some
asymptomatic cases.
Receipt of seasonal vaccination within the preceding 2 years
did not appear to influence prevaccination seroprotection rates
in our studies. This does not rule out cross-reactive priming by
previous seasonal vaccination as HI titers at baseline may not
be the most appropriate parameter to detect prior immune
activation. Also, even if some level of cross-reactive HI re-
sponse was induced by prior seasonal vaccination, it may not
have been strong enough to be still detectable 1 to 2 years later.
In another vaccination study, it was reported that baseline
A/H1N1/2009 HI antibody levels were higher in adults, but not
children, with seasonal vaccination in any of the five preceding
years (29). The authors suggested, however, that seasonal in-
fluenza vaccination may have been a confounder of another
factor, such as exposure (by infection or vaccination) to strains
with similar epitopes which were in circulation prior to the
2004-2005 season (29). In children, Cowling et al. (8) found
little cross-reactive neutralizing antibody response to A/H1N1/
2009 virus following 2008 seasonal influenza vaccination but
did find statistically significant cross-reactive responses to
A/H1N1/2009 in those who had seasonal A/H1N1 infection,
although few individuals had antibody titers of1:40. Hancock
et al. (17) also concluded that recent seasonal influenza vac-
cines induced little or no cross-reactive antibody responses to
A/H1N1/2009.
In the case of H5N1 vaccination, the use of AS03 was found
to significantly decrease the amount of antigen required to
elicit an acceptable response (22). A similar effect of AS03 on
A/H1N1/2009 was exemplified in study B, where adjuvanted
and nonadjuvanted formulations were compared at the
same 3.75-g-HA dosage and the HI GMTs following both
the first and the second vaccinations were higher for the
AS03A-adjuvanted formulation. Furthermore, in terms of the
kinetics of the HI immune response, the adjuvanted formula-
tion induced a further increase in HI antibody levels after the
second vaccination, whereas for the nonadjuvanted formula-
tion, the increase was more modest. This is clearly evident in
study A, where comparable GMTs were observed after the first
vaccination for the AS03A-adjuvanted 3.75-g HA and nonad-
juvanted 15-g HA formulations, whereas after the second
vaccination, the GMT was higher for the AS03A-adjuvanted
formulation. Greenberg et al. (16) also observed that a second
dose of nonadjuvanted A/H1N1/2009 vaccine conferred little
additional benefit in terms of HI responses in adults. This
difference in the kinetics of the HI immune response between
adjuvanted and nonadjuvanted formulations was also observed
for H5N1 (22).
As we lack precise knowledge on what a well-validated pro-
tective antibody level is, in particular for this new A/California
strain, the clinical implications of a higher GMT for AS03A-
adjuvanted vaccine are not clear. Apart from promoting better
antibody persistence, it may, for example, signal a difference in
the quality of the priming of the B-cell or CD4 T-cell memory
response. In this respect, it is of note that in study A, although
the antibody GMTs were comparable on day 21 after one dose,
a post hoc inferential analysis indicated that the frequency of
H1-specific CD4 T cells was higher in the AS03A-adjuvanted
group than that in the nonadjuvanted group. Furthermore,
after a second dose, this difference between the groups was
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sustained, resulting in significantly higher H1N1- and H1-spe-
cific CD4 T-cell response amplitudes over the 42-day period,
which mirrors the difference in HI antibody response kinetics
between the groups over the same period. Studies on A/H1N1/
2009 booster vaccination (following both one- and two-dose
primary schedules) should provide further information on the
quality of priming with and without AS03A in terms of the
induction of immune memory as monitored by both antibody
and CD4 T-cell responses. We also performed a post hoc
analysis to examine whether preexisting CD4 T-cell immunity
could (partially) explain the variability of the postvaccination
HI antibody responses. Our observations indicated that pre-
vaccination CD4 T-cell immunity did not predict antibody
responses as no evidence of a relationship was found between
the frequency of A/H1N1/2009-specific CD4 T cells at base-
line (day 0) and the post-dose 1 HI antibody titer at day 21. A
moderate level of correlation was, however, observed between
the frequency of A/H1N1/2009-specific CD4 T cells at day 21
and the post-dose 2 HI antibody titer at day 42. It may be that
we observed such a correlation between A/H1N1/2009-specific
CD4 T cells and HI antibody levels only after the first vaccine
dose because the post-dose 1 CD4 memory pool is more ho-
mogeneous and specific for the A/H1N1/2009 vaccine, whereas
the CD4 memory population before vaccination is more het-
erogeneous and is likely to be the consequence of a more
complex cross-reactive immunity arising from previous influ-
enza vaccinations or infections. In that setting, the vaccine
amplifies a rare A/H1N1/2009-specific memory population—
the frequencies of these rare cells may not be reflected in the
total prevaccination frequency. Further studies, specifically de-
signed to assess immune markers as predictors of responses to
vaccination, are required to confirm this correlation.
Although we could not discern a clear effect of seasonal
vaccination within the preceding 2 years on prevaccination
status, there was a consistent trend, in both studies and for
both AS03A-adjuvanted and nonadjuvanted A/H1N1/2009 vac-
cines, of a diminished HI antibody response in subjects who
had previously received seasonal vaccine. Plennevaux et al.
(29) also reported that previous seasonal influenza vaccina-
tion was associated with a lower HI GMT after a first dose
of nonadjuvanted A/H1N1/2009 vaccine. Similarly prior vacci-
nation with either seasonal influenza vaccine (10, 28) or non-
adjuvanted H5N1 vaccine (23) was found to have a negative
impact on immune responses to subsequent H5N1 vaccination.
The immunological mechanisms underlying this phenomenon
and its clinical implications are not clear. Cowling et al. (8)
reported that children aged 6 to 15 years who received seasonal
trivalent influenza vaccine (TIV) in 2008 were found to have
nonstatistically significant higher rates of subsequent serolog-
ically confirmed infection with A/H1N1/2009 in 2009, although
no clinical differences were noted in terms of influenza-like
illness (ILI) attack rates compared to subjects who did not
receive TIV. Wrammert et al. (41) have demonstrated that
influenza TIV vaccination expands rare memory B cells that
have very high specificity for the vaccine, showing that the
vaccine was very efficient at capturing preexisting memory.
Should seasonal TIV vaccination actually have the ability to
change this existing memory B-cell population, it is likely
that subsequent vaccination will be affected by this change.
Whether that is positive or negative likely depends on the level
of cross-reactivity conferred by the initial seasonal vaccination.
Therefore, it is possible that previous nonadjuvanted seasonal
influenza vaccination leads to a “skewing” of the T-cell and/or
B-cell repertoires toward epitopes specific for those vaccines,
thus limiting the selection and expansion of those T- and B-cell
clones that display the strongest specificity for A/H1N1/2009
(28, 31). Clearly, the influence of previous seasonal vaccination
on responses to A/H1N1/2009 vaccination and the potential
impact of adjuvant in this process warrant further in depth
investigation.
In conclusion, the AS03A adjuvant system enhances the hu-
moral and CD4 T-cell-mediated responses to A/H1N1/2009
vaccine. Baseline A/H1N1/2009-specific CD4 T-cell frequen-
cies do not seem to predict post-dose 1 antibody responses,
although a correlation suggests a relationship between post-
dose 1 CD4 T-cell frequencies and post-dose 2 antibody
responses.
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